BioPharma Today

Coming In Monday's "The Pink Sheet" DAILY - Oncology Drug Updates

Wendy Diller — Fri, 19 Mar 2010 10:33:27 PDT

FDA’s Oncologic Drugs Advisory Committee will review Cell Therapeutics’ Pixuvri for non-Hodgkin’s lymphoma Monday, and determine if the drug has enough evidence for approval despite an early halt to a Phase III trial.

Pharma Market-Share Fees In House Health Care Reform Package Less Than Expected

Josh — Fri, 19 Mar 2010 08:23:16 PDT

The House's new proposed changes to the Senate health care reform bill leave brand drug manufacturers relatively unscathed, since they will pay only an additional $5 billion in fees over 10 years while still gaining an elimination of the Medicare Part D coverage gap.

Latest News From "The Pink Sheet" DAILY - Teva Wins Ratiopharm

Wendy Diller — Fri, 19 Mar 2010 06:12:20 PDT

Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe

Coming in Friday's "The Pink Sheet" DAILY - Teva Wins Battle To Buy ratiopharm

Wendy Diller — Thu, 18 Mar 2010 10:34:40 PDT

Teva wins the bidding war for Germany's ratiopharm - House of Representatives releases details on its updated health care reform package - NIH is creating a registry of genetic tests - Pfizer dimisses suit alleging Lilly's Cialis infringes its Viagra patent

Latest News From "The Pink Sheet" DAILY - PhRMA Helps Roll-Out New Health Reform Ad Campaign

Wendy Diller — Thu, 18 Mar 2010 07:07:00 PDT

Russell Greig leaves GSK's corporate venture group - PhRMA backs new health reform ad campaign - Unigene restructures its debt - Merck and Teva settle Temodar patent suit - PTO ordered to reconsider The Medicines Co.'s request for Angiomax patent extension - Sucampo requests arbitration to terminate its Amitiza partnership with Takeda - Sen. Hatch prompts provision in steroid bill to require FDA to publish NDI notification

Editors' Picks From the World Press

Wendy Diller — Thu, 18 Mar 2010 06:55:07 PDT

Pipeline/RD News Study: Regadenoson appears better for heart transplant patients Green alga holds promise for pharmaceutical production Study: Inhibiting gene in mice causes cancer cells to age HGS drug doesn't extend survival for lung cancer patients in study Business Finance...

Coming in Thursday's "The Pink Sheet" DAILY - Legal Spotlight On The Medicines Company & Teva

Wendy Diller — Wed, 17 Mar 2010 10:07:30 PDT

The Medicines Company may yet win its long battle to extend the patent term on its anticoagulent Angiomax - Teva reached a settlement with Merck to resolve patent litigation over Teva's generic version of the brain cancer drug Temodar - Cash-strapped Unigene Laboratories bought itself some time March 17 with a debt restructuring that brings it $13.6 million in operating cash while increasing its outstanding debt to principal shareholder Victory Park Capital Advisors and moving back the due date for repayment of that debt by about 18 months.

Latest News from "The Pink Sheet" DAILY - ACC Updates On Tekturna

Wendy Diller — Wed, 17 Mar 2010 07:00:19 PDT

Way To Close Medicare Part D Gap Depends On CBO Numbers And Legislative Options - Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna - Merck Expands Outsourcing With Zhejiang Huahai For HIV Finished Product Manufacturing

Editors' Picks from the World Press

Wendy Diller — Wed, 17 Mar 2010 06:55:02 PDT

Pipeline/RD News BioTime touts early results of research on iPS cell technology Genetic test reduces warfarin-related hospitalization, study finds Study: Drug-coated stents increase risk of heart-related death Business Finance Warehouse heist costs Lilly $75 million in prescription drugs Publix offers...

Coming In Wednesday's "The Pink Sheet" DAILY - AstraZeneca Talks Emerging Markets, Promedior Raises $12 million in a Series C Round

Wendy Diller — Tue, 16 Mar 2010 10:06:34 PDT

AstraZeneca outlines ‘focused’ branded generics plan within broader emerging markets strategy - Novo Growth Equity’s $30 million investment in Sweden’s Orexo, following just two weeks behind its first, even larger financing, in the UK’s Archimedes, proves the continued appeal of low-risk European specialty pharma - In its second venture round in roughly a year, Promedior raised $12 million in a Series C round led by new investor Forbion Capital Partners.

Latest News from "The Pink Sheet" DAILY - OSI Board Rejects Astellas

Wendy Diller — Tue, 16 Mar 2010 06:58:08 PDT

OSI Board Rejects Astellas, Seeks Other Bids - FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says - FDA Explores New Approaches To Predict Drug Safety Issues

Editors' Picks from the World Press

Wendy Diller — Tue, 16 Mar 2010 06:50:49 PDT

Pipeline/RD News Angiotech: Taxus Element stent meets endpoint in 2 clinical trials Lower dose of betrixaban reduces bleeding in midstage study Business Finance Report: Life sciences firms raised $1.9B in Q4 venture funding Former Schering-Plough executives will lead Bausch Lomb...

Coming In Tuesday's "The Pink Sheet" DAILY - OSI Rejects Astellas' Hostile Bid

Wendy Diller — Mon, 15 Mar 2010 10:12:20 PDT

OSI's board of directors formally responded with a resounding no to Astellas' $52-a-share hostile takeover bid.

FDA Wants More REMS Authority To Speed Negotiations With Sponsors

Josh — Mon, 15 Mar 2010 08:33:58 PDT

Full Article reprinted from "The Pink Sheet"- March 15, 2010 FDA would like Congress to provide the agency with a larger role in writing Risk Evaluation and Mitigation Strategies, Principal Deputy Commissioner Joshua Sharfstein indicated during a House Energy and Commerce Health Subcommittee hearing on March 10. Read more...

Latest News From "The Pink Sheet" DAILY - Abbott TriCor ACCORD Data Presented At ACC

Wendy Diller — Mon, 15 Mar 2010 06:41:30 PDT

Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD.

Coming in Monday's "The Pink Sheet" DAILY - Plavix Gets Boxed Warning

Wendy Diller — Fri, 12 Mar 2010 10:43:20 PST

Europe's regulators are meeting with key health technology assessment (HTA) bodies and taking steps to make advisory committee meetings more accessible. - FDA added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that it can be less effective in people who cannot metabolize the drug to convert it to its active form.